Table 3.
Presence or Absence of MICA and Hyperplasia at Baseline and after Treatment in EXE and SAL Groups
| Variables | EXE, n = 26 | SAL, n = 26 | P value |
|---|---|---|---|
| No. of cases of newly identified MICA at study end | 8 | 6 | 0.31 |
| No. of samples without MICA before and after treatment | 9 | 16 | 0.31 |
| No. of samples with MICA at baseline | 9 | 4 | 0.49 |
| No. of cases of new identified hyperplasia at study end | 14 | 9 | 0.21 |
| No. of samples without hyperplasia before and after treatment | 8 | 14 | 0.21 |
| No. of samples with hyperplasia at baseline | 4 | 3 | 1.0 |
All comparisons between EXE and SAL group were performed by Fisher's exact test.
EXE, exenatide; MICA, mononuclear inflammatory cell accumulation; SAL, saline.